Evidence map›Paper›PMID 35316308›Full record

ArticlePLoS pathogens2022

Targeting the BspC-vimentin interaction to develop anti-virulence therapies during Group B streptococcal meningitis.

Haider S Manzer, Ricardo I Villarreal, Kelly S Doran

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. The Clinical and Genetic Characteristics ofInternational journal of molecular sciences · 2023
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Haider S ManzerUniversity of Colorado Anschutz Medical Campus, Department of Immunology and Microbiology, Aurora, Colorado, United States of America.
Ricardo I VillarrealUniversity of Colorado Anschutz Medical Campus, Department of Immunology and Microbiology, Aurora, Colorado, United States of America.
Kelly S DoranUniversity of Colorado Anschutz Medical Campus, Department of Immunology and Microbiology, Aurora, Colorado, United States of America.ORCID 0000-0003-4232-6837
University of Colorado Anschutz Medical Campus · US

Funding

Molecular Pathogenesis of Infectious DiseasesT32AI052066 · NIAID · UNIVERSITY OF COLORADO DENVER · PI VAN DYK, LINDA F. · 2002 to 2022
$2.3M
Modulation of Blood-Brain Barrier Defense and Dysfunction during Bacterial MeningitisR01NS116716 · NINDS · UNIVERSITY OF COLORADO DENVER · PI DORAN, KELLY S · 2020 to 2024
$1.9M
Characterizing the Contribution of the Group B Streptococcal Surface Adhesin BspC Interaction with Host Vimentin to Disease and ColonizationF31AI164674 · NIAID · UNIVERSITY OF COLORADO DENVER · PI MANZER, HAIDER SYED · 2021 to 2022
$69k
NIAID NIH HHS F31 AI164674NIAID NIH HHS T32 AI052066NINDS NIH HHS R01 NS116716
6 · The paper itself

Abstract

Bacterial infections are a major cause of morbidity and mortality worldwide and the rise of antibiotic resistance necessitates development of alternative treatments. Pathogen adhesins that bind to host cells initiate disease pathogenesis and represent potential therapeutic targets. We have shown previously that the BspC adhesin in Group B Streptococcus (GBS), the leading cause of bacterial neonatal meningitis, interacts with host vimentin to promote attachment to brain endothelium and disease development. Here we determined that the BspC variable (V-) domain contains the vimentin binding site and promotes GBS adherence to brain endothelium. Site directed mutagenesis identified a binding pocket necessary for GBS host cell interaction and development of meningitis. Using a virtual structure-based drug screen we identified compounds that targeted the V-domain binding pocket, which blocked GBS adherence and entry into the brain in vivo. These data indicate the utility of targeting the pathogen-host interface to develop anti-virulence therapeutics.

Indexed as

Meningitis, BacterialStreptococcal InfectionsAdhesins, BacterialHumansInfant, NewbornStreptococcus agalactiaeVimentinVirulenceAdhesins, BacterialVimentin

Identifiers

PMID35316308
PMCPMC8939794
OpenAlexW4220654264

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.